Hereditary canine spinal muscular atrophy (HCSMA) is an autosomal dominant motor neuron disease that is similar in pathology and clinical presentation to various forms of human motor neuron disease. We have tested the hypothesis that the canine survival motor neuron (SMN) gene is responsible for HCSMA by genetic and molecular analysis of a colony of mixed breed dogs, all descended from a single affected individual. We cloned the canine SMN gene and determined the DNA sequence in an affected and an unaffected dog. We found no germline mutations in the SMN gene of the affected individual. Using conventional linkage analysis with canine-specific microsatellite repeat markers we screened the canine genome and identified a single linkage group likely to contain the HCSMA gene. Analysis with a panel of canine/rodent hybrid cell lines revealed that the SMN gene did not map to the same chromosome as the HCSMA linkage group. Collectively these results suggest that the molecular basis for HCSMA is distinct from that of phenotypically similar human disorders caused by inherited mutations in the SMN gene. This further suggests that additional studies on the molecular nature of HCSMA may reveal an unknown element of the molecular pathway leading to motor neuron disease.
Hereditary canine spinal muscular atrophy (HCSMA) is an autosomal dominant motor neuron disease that is similar in pathology and clinical presentation to various forms of human motor neuron disease. We have tested the hypothesis that the canine survival motor neuron (SMN) gene is responsible for HCSMA by genetic and molecular analysis of a colony of mixed breed dogs, all descended from a single affected individual. We cloned the canine SMN gene and determined the DNA sequence in an affected and an unaffected dog. We found no germline mutations in the SMN gene of the affected individual. Using conventional linkage analysis with canine-specific microsatellite repeat markers we screened the canine genome and identified a single linkage group likely to contain the HCSMA gene. Analysis with a panel of canine/rodent hybrid cell lines revealed that the SMN gene did not map to the same chromosome as the HCSMA linkage group. Collectively these results suggest that the molecular basis for HCSMA is distinct from that of phenotypically similar human disorders caused by inherited mutations in the SMN gene. This further suggests that additional studies on the molecular nature of HCSMA may reveal an unknown element of the molecular pathway leading to motor neuron disease.
Hereditary canine spinal muscular atrophy ( HCSMA) is an autosomal dominant disorder which has clinical and pathologic features reminiscent of those seen in human motor neuron diseases (Cork et al. , 1982 Lorenz et al. 1979) . In affected animals, weakness is progressive with fasciculations and muscle atrophy. Single motor unit electrophysiology documents a dysfunction in neurotransmission in the most peripheral parts of the axon that is responsive to 4-aminopyridine (Pinter et al. 1995 (Pinter et al. , 1997 . Spinal cord lesions include chromatolysis, axonal swellings filled with neurofilaments, and eventually motor neuron death (Cork et al. , 1982 . These features are also seen in both the human diseases amyotrophic lateral sclerosis and spinal muscular atrophy ( Byers and Banker 1961; Carpenter 1968; Chou and Fakadej 1971; Hirano and Iwata 1979) . The abnormalities in glutamate metabolism documented in amyotrophic lateral sclerosis (Rothstein et al. 1992 ) have also been demonstrated in HCSMA ( Tsai et al. 1993 ).
HCSMA was originally described in a single male Brittany spaniel dog (Cork et al. , 1990 . A colony of HCSMA affected dogs was developed by inbreeding dogs produced from a mating between the sister and the father of the dog in which the diagnosis was originally described (Sack et al. 1984) . The colony was maintained at the Johns Hopkins University School of Medicine and is now at Stanford University Medical School. Descendants from the single founder appear to have distinct forms of the disease (Sack et al. 1984) . Dogs with an accelerated phenotype are profoundly affected; they develop weakness at between 6 and 8 weeks of age and progress rapidly to complete tetraparesis by 13-20 weeks. This is similar to the infantile forms of human spinal muscular atrophy disease. Clinical disease progresses more slowly in other dogs and is more analogous to the juvenile and adult forms of spinal muscular atrophy. These dogs become weak during the first year of life and progress to paresis over several years. Because the colony has been maintained by the breeding of some closely related animals, the variation in phenotype is consistent with a gene dose effect; dogs that carry one copy of a mutated gene have a milder disease, but the most severely affected dogs are presumed homozygotes (Sack et al. 1984) . Approximately equal numbers of males and females are affected and with equal distribution of phenotypes.
Because of the similarity between the (Sack et al. 1984) . We were interested specifically in testing the hypothesis that genes involved in human motor neuron disease play a role in HCSMA. All three forms of human spinal muscular atrophy map to chromosome 5q11.2-q13.3 Gilliam et al. 1990; Melki et al. 1990; Sheth et al. 1991; Soares et al. 1993) . Two genes have been described which appear to play a key role in the human spinal muscular atrophy disorders. The first of these is the neuronal apoptosis inhibitor protein ( NAIP), which has been mapped to human chromosome 5q13.1 and is homologous to baculoviral apoptosis inhibitor proteins (Roy et al. 1995) . Initial studies of this gene in spinal muscular atrophy patients showed that the first two coding exons of this gene are deleted in 67% of spinal muscular atrophy chromosomes compared with 2% of nonspinal muscular atrophy chromosomes.
The second gene proposed to play a role in the human spinal muscular atrophies is the survival motor neuron gene (SMN), which also maps to 5q13 . There are two copies of this gene on chromosome 5 due to a 500 kb duplication. One copy has been shown to be deleted or interrupted in nearly 95% of spinal muscular atrophy patients ( Bussaglia et al. 1995; Lefebvre et al. 1995; Rudnik-Schoneborn et al. 1996; Zappata et al. 1996) . Additional studies showed that the same deletion frequency is observed in patients with severe and mild forms of the disease (Rodrigues et al. 1995) . Comparative analysis of the SMN and NAIP genes consistently indicate that SMN is homozygously deleted in a significantly higher percentage of spinal muscular atrophy patients than is NAIP . We applied recently developed resources from the canine genome project to test the hypothesis that inherited mutations in the canine SMN gene result in HCSMA.
Material and Methods

HCSMA Status
Phenotype was assigned on the basis of observed rate of progression of disease and the clinical and pathologic criteria described previously (Sack et al. 1984) . Individual health records were maintained for each dog from birth. The phenotype of dogs with accelerated disease was easy to determine. However, it was sometimes difficult to distinguish dogs with no disease from those with a mild phenotype. Dogs in the pedigree had muscle biopsies for diagnosis at approximately 6 months of age. Biopsies were repeated for verification. Only dogs with accelerated disease, or dogs whose offspring indicated they were certain carriers of HCSMA, were used in these analyses. All DNA samples used in the above studies were supplied from dogs that had been housed under protocols approved by the Institutional Animal Care and Use Committee of the Johns Hopkins School of Medicine and in accordance with the municipal, state, and federal laws governing animal welfare.
Canine DNA Preparation
Genomic DNA from pedigree dogs used in the genetic linkage analysis was prepared using standard protocols. Canine cDNA used to sequence the SMN gene was prepared from total RNA isolated from 100 mg of beagle testis using RNAStat-60 ( TelTestB Inc.) and the manufacturer's suggested protocols. This dog was unrelated to others in the pedigree and was unaffected. For DNA sequence comparison, mRNA from a single profoundly affected dog was isolated from 1 g testis tissue using an mRNA isolation system kit (GibcoBRL Life Technologies; Gaithersburg, Maryland). First-strand cDNA synthesis for both of the above samples was performed using an oligo(dT ) 12-18 as outlined in the SuperScript preamplification system for first strand cDNA synthesis kit (GibcoBRL Life Technologies).
Cloning and Sequencing the Canine SMN Gene
Primers which amplify coding sequence from human SMN exons were synthesized using the published human SMN sequence . Canine SMN exons were amplified from first-strand cDNA prepared from an unaffected and unrelated beagle using human SMN primers in all possible combinations ( Table 1) using standard conditions and 35 cycles of amplification at 95ЊC for 15 s; 50ЊC for 15 s; 72ЊC for 15s. Canine SMN exon bands were excised from a 4% denaturing gel, diluted in 100 ml 10 mM Tris-HCl, PCR amplified, and sequenced. Canine SMN-specific primers were identified from this sequence. The 3Ј and 5Ј ends of canine SMN were cloned from beagle testis total RNA using the rapid amplification of cDNA ends (RACE) method and canine-specific SMN primers. To verify the canine SMN sequence PCR products amplified with canine primers were cloned into either the Invitrogen PCR II vector using the Original TA Cloning Kit ( Invitrogen; San Diego, California), or into the Promega pGEM-T vector (Madison), using the pGEM-T vector systems kit. Single clones were sequenced using the Dye Deoxy terminator cycle sequencing kit (Applied Biosystems) on an ABI 373A sequencer. Sequences were assembled and analyzed with the SeqEd program for Macintosh (Applied Biosystems).
Sequence Analysis of a Severely Affected Dog
The complete cDNA sequence was derived from a severely affected male HCSMA dog, age 180 days, whose clinical condition and muscle biopsy were consistent with accelerated disease. Canine SMN cDNA was amplified using the canine-specific SMN primers SMN 1dx and SMN 8dy ( Table 2 ) and the standard conditions described above. PCR products were purified using the Qiagen PCR quick spin purification kit. Overlapping sequence was obtained using canine-specific primers SMN 1dx, 3dx, 5dx, 8dx, 2dy, 4dy, 6dy, and 8dy and Dye Deoxy terminator cycle sequencing.
Genotyping
Canine-specific microsatellite markers and methods for microsatallite analysis have been described previously ( Francisco et al. 1996; Ostrander et al. 1995) . Markers used contained either di or tetra nucleotide repeats and had polymorphic information content (PIC) values ranging from 0.5 to 0.8. All genotypes were scored in- dependently by two researchers. Results were compared and differences identified and resolved.
Canine Reference Pedigrees
The framework genetic map of the linkage group containing markers linked to HCSMA was constructed by genotyping a reference panel of 17 three-generation pedigrees derived from various ancestral strains, including purebred miniature and toy poodles, Norwegian elkhounds, Irish setters, and several genetically distinct strains of laboratory beagles (Mellersh et al. 1997) . The panel contained 212 individuals, including 163 F 2 offspring. None of the dogs in the reference panel was affected with HCSMA.
Linkage Analysis
Two-point recombination fractions and associated LOD scores between HCSMA and canine-specific polymorphic microsatellite markers were calculated using the program MultiMap (Matise et al. 1994) . A sexaveraged framework map for the linkage group containing two markers putatively linked to HCSMA was also constructed with MultiMap using genotyping data generated from the panel of reference pedigrees. Markers were analyzed in order of decreasing informativeness and were added to the framework map if they mapped to a unique interval with odds Ն1,000:1.
Canine/Rodent Hybrid Cell Lines
DNA from a panel of 47 canine/rodent hybrid cell lines ( Langston et al. 1997 ) was amplified with primers for 147 canine-specific microsatellites, as well as the SMN gene, to investigate whether the SMN gene was on the same chromosome as markers linked to HCSMA. Approximately 200 ng of genomic DNA from each hybrid cell line were amplified using PCR conditions similar to those used for genotyping.
Results
Canine Model of HCSMA
The HCSMA colony examined in this study was established in 1975 from a Brittany spaniel bitch and her progeny sired by her father. Subsequent matings were entirely between descendants of these original dogs, with the exception of two purposebred beagles introduced to increase the informativeness of the colony. Introduction of one of these dogs, FV09, was key in outbreeding the portion of the pedigree used in this study ( Figure 1 ). Because the canine disease is similar to previously reported human motor neuron diseases, we used both a candidate gene approach and conventional linkage analysis to investigate the role of the SMN gene in HCSMA.
Cloning and Sequencing the Canine SMN Gene
We cloned and sequenced the canine SMN gene from affected and unaffected dogs to test the possibility that germline mutations in this gene are responsible for HCSMA. Canine SMN was amplified by PCR and cloned from first-strand canine cDNA prepared from an unrelated and unaffected beagle using a set of PCR primers derived from the sequence of the human SMN gene ( Table 1) . Overlapping cDNA clones were analyzed and the sequence determined. The nucleotide sequence of the canine coding regions is 89.5% identical to the human sequence ( Figure 2 ). The amino acid identity is 87.6%, while the similarity is 97.6%. The nucleotide sequence has been submitted to GenBank (accession number U50746).
To confirm we had cloned and sequenced the canine SMN gene, DNA from three unrelated dogs and one human was amplified using the canine-specific primers SMN d4 and the PCR products analyzed on an ethidium bromide-stained agarose gel. PCR products were only generated with canine DNA, which confirmed the primers and corresponding sequence were canine-specific (data not shown).
Using canine-specific primers listed in Table 2 , we then cloned and sequenced the coding region and intron/exon boundaries of the SMN gene from a profoundly affected dog descended from a mating of two moderately affected dogs. A comparison of the SMN sequence from the affected and unaffected dogs revealed only two changes; an A to G substitution at base 777 and a T to A substitution at base 911. The first change does not alter the amino acid sequence and the second is in a noncoding region, a significant distance from any splice junction. It is unlikely, therefore, that either change is significant; these data suggest that inherited mutations in the coding region of the canine SMN gene are not responsible for HCSMA.
Linkage Analysis
Previous studies indicated that HCSMA was due to the action of a single autosomal dominant gene (Sack et al. 1984) . Because our data suggests the SMN gene is not responsible for HCSMA, we used conventional linkage analysis to identify genetic markers linked to the disease. Sixteen individuals representing a large nuclear family from the HCSMA pedigree were genotyped with approximately 150 canine-specific microsatellite markers ( Francisco et al. 1996; Ostrander et al. 1993 Ostrander et al. , 1995 . The individuals analyzed are shown in Figure 1 . Other parts of the pedigree were found to be too inbred for informative genotyping. We calculated twopoint recombination fractions and associated LOD scores between HCSMA and each marker. Two markers showed evidence of linkage to HCSMA. Marker 424 yielded a recombination fraction of 0.091 with HCSMA, supported by a LOD score of 1.85, and marker 673 yielded a recombination fraction of 0.182, supported by a LOD score of 1.05. Markers 424 and 673 map to the same linkage group.
Data obtained from a panel of canine/ rodent hybrid cell lines identified six additional markers (2016, 2294, 2309, 246, 251, and 643) likely to be on the same chromosome as 424 and 673. Linkage analysis demonstrated that each of the eight markers were linked to at least one other marker with a recombination fraction Յ0.4 and a LOD score of at least 3.0. Thus these markers represent a single linkage group. We genotyped all eight markers in this linkage group in our reference pedigrees and constructed a framework genetic map of the linkage group. Six markers (2016, 673, 246, 2294, 2309, and 424) were placed on the framework map, with each marker mapping uniquely to a specific map position with a LOD score of at least 3.0 ( Figure 3) . Marker-specific primer sequences are listed in Table 3 . We genotyped the six additional markers in the HCSMA dogs. Only markers 2309 and 643 were informa- Figure 1 . HCSMA pedigree analyzed for these studies. This is a subset of dogs from a much larger colony covering more than 10 generations (Sack et al. 1984) . tive in the pedigree and neither showed any evidence of linkage to HCSMA.
Chromosomal Analysis
Our experiments suggested that mutations in the coding region of SMN were not responsible for HCSMA. However, these experiments did not exclude the possibility that changes in the level of SMN protein, caused, for example, by mutations in upstream regulatory elements, were responsible for the disease. To obtain further evidence of whether the SMN gene is associated with HCSMA, we tested whether the canine SMN gene mapped to the same chromosome as the HCSMA linkage group containing markers 424 and 673. DNA from a panel of 47 canine/rodent hybrid cell lines was amplified with primers from the canine SMN gene and with primers for 147 canine-specific microsatellites (including markers in the linkage group containing 424 and 673). Most of the cell lines contained between 1 and 4 canine chromosomes in a rodent background and most of the canine genome was represented in the panel ( Langston et al. 1997) . We observed that SMN amplified DNA from cell lines MDE2, MDL1, LAD1-2, and LAD1-12. In contrast, the two markers that were genetically linked to HCSMA amplified DNA from cell lines MDE4, MDL7, LAD1-8, LAD2-4, and LAD4-15. In summary, there was no overlap between the subset of cell lines which generated an SMN product and those which amplified with markers in the linkage group containing marker 424, suggesting the genetic defect which causes HCSMA is located on a different chromosome from the SMN gene. Finally, the 10 markers which did amplify DNA from a similar subset of cell lines as the SMN gene were genotyped in the HCSMA pedigree. Since we don't know that these markers span the entire chromosome, this experiment cannot provide formal proof that SMN is uninvolved in HCSMA. But the data were consistent in that none showed any evidence of linkage to HCSMA in the pedigree.
Discussion
Spinal muscular atrophy is the second most common fatal autosomal recessive disorder after cystic fibrosis, and occurs in 1 in 6,000 newborns (Pearn 1973 (Pearn , 1978 Roberts et al. 1970) . The spinal muscular atrophies are characterized by degeneration of the anterior horn cells of the spinal cord, which leads to progressive symmetrical limb and trunk paralysis associated with muscular atrophy. The symptoms of HCSMA resemble those of human motor neuron diseases. Hence studies of this canine disease may provide important insights into the biology of similar human conditions.
The HCSMA pedigree analyzed in this study is well suited to genetic dissection. First, although HCSMA is autosomal dominant, the pedigree is inbred, and as a result both homozygote and heterozygote affected animals are available for study and the phenotypic differences between them may be examined. It should be noted, however, that the high level of inbreeding has resulted in a reduction in the genetic heterogeneity of the pedigree and thus its overall usefulness for genetic mapping. Second, because this HCSMA colony was established from a single founder and is maintained by mating closely related individuals, all dogs carry the same mutation. This simplifies statistical analysis substantially. Finally, the pedigree is large, with DNA, tissue, and sperm samples available from over 260 individuals. The opportunity to genetically analyze very large numbers of affected individuals from the same family offers great advantages from a statistical viewpoint because the mistake of genotyping and adding LOD scores from families with phenotypically similar but different disorders is avoided. In rare instances such families have been successfully used to map human genetic disorders, such as Huntington's disease where a single large Venezuelan pedigree was studied (Gusella et al. 1983 ) and primary postlingual deafness where 99 family members descended from a single affected founder in Costa Rica were available for genotyping ( Leon et al. 1992) .
Two candidate genes for childhood onset spinal muscular atrophy have been reported. The survival motor neuron gene is the most likely to play a key role, and is present in the human genome as two highly homologous copies (telSMN and cen-SMN) within the spinal muscular atrophy candidate region (5q11.2-q13.3) ( Burglen et al. 1996; Bussaglia et al. 1995) . Regardless of the severity of the disease, 90-98% of spinal muscular atrophy patients carry homozygous deletions in telSMN, affecting either exon 7 or both exon 7 and 8. Because of the similarity between HCSMA and human spinal muscular atrophy, we took a candidate gene approach to investigate the molecular basis of the canine disease, focusing attention on the SMN gene. The high degree of homology between the human and canine genes allowed rapid cloning of the canine gene. Because the HCSMA pedigree is inbred and all affected individuals are descended from a single founder they will all share the same genetic defect. The lack of differences between the sequence of an affected and unaffected dog, however, suggested that mutations in the SMN coding region are not responsible for HCSMA. In the case of the human gene, subtle polymorphisms distinguish between the critical telomeric copy and the unassociated centromeric copy. In the case of the dog, neither DNA sequence analysis nor single-stranded confirmation polymorphism analysis (SSCP) on genomic DNA revealed a second SMN gene (data not shown).
Additional supporting evidence to support the conclusion that inherited mutations in SMN are not responsible for HCSMA came from linkage analysis of the HCSMA pedigree. Five of 10 markers shown to be physically linked to the SMN gene by cell line mapping were informative in the HCSMA pedigree; none showed any evidence of linkage to HCSMA ( LOD scores Յ 0). Our results suggested, therefore, that the SMN region is not associated with HCSMA, despite the profound similar- GACTTCATTCATCCATTCATGA  TACCACTGTCATTTTTCCATGC  AGCTTAGCTTACTGCCCTGG  AAGTCTCCTGACGATGAACACA  CCACCACTTACATAAACATGGC  CATTTTTAAGGATGGAGACAGC  GGGTCCTGGGATCAAGCC  GACTGAGTTCTTTCAGCACAGTG   GGATCGAGTCCAACGTGG  AAGAGGATACCGGTGGCAG  TCCTTTGGTTTTTAGCAGGG  CCTAGAGTCTGCTGGAGATTGC  TTCCAGACTGCTGCCTCC  AACAGTGTCCCATGGCCTAC  TTAGTAAAGAGACAGCTGATTGCC  GGCAGCCTTATTATTCATGGA   127  146  186  155  162  318  227  380 ities between this disease and human spinal muscular atrophy. In addition to SMN, the neuronal apoptosis inhibitor protein gene ( NAIP) has been implicated in some cases of spinal muscular atrophy in man (Roy et al. 1995) . SMN and NAIP are located physically close to one another on human 5q. Although our studies indicate SMN does not cause HCSMA, NAIP has not been excluded. We have shown the locus responsible for HCSMA is not syntenic with the SMN gene, which would also exclude NAIP, if NAIP and SMN are syntenic in dogs. Unfortunately there is little available information regarding the syntenic relationships between human and canine chromosomes. It is theoretically possible, however, that a rearrangement has occurred in dogs in the region between NAIP and SMN, and that NAIP is located on the same chromosome as the linkage group containing markers 424 and 673. Thus we are not able to formally exclude NAIP as the gene responsible for HCSMA, although we consider it unlikely.
Previous studies were consistent with the model that HCSMA is caused by mutations in a single autosomal dominant gene (Sack et al. 1984 (Sack et al. , 1996 . Thus we used linkage analysis on the most outbred and hence most informative portion of the HCSMA pedigree to identify the region of the genome linked to HCSMA. The two markers which gave provocative two-point LOD scores with HCSMA were found to map within 31 cM of each other. Generally genetic linkage between two loci is accepted if a recombination fraction of Ͻ0.5 is supported by a LOD score of Ն3.0, indicative of odds of Ͼ1,000:1 in favor of linkage. The highly inbred nature of this particular pedigree limited our analysis. The small size of the informative part of the pedigree available for analysis meant only a recombination fraction of zero would be supported by a LOD score of Ն3.0. Linkage between marker 424 and HCSMA is supported by a LOD score of 1.85, which is the maximum possible support for linkage obtainable, given that at least one recombination event is observed between marker and disease in the 11 meioses. Markers 424 and 673 belong to a linkage group containing six other microsatellite markers (2016, 246, 2309, 251, and 2294) ( Figure 3) . Six of the eight markers can be placed in unique intervals on the framework genetic map of this group, with the order and spacing supported by odds of Ͼ1,000:1. The HCSMA locus could not be positioned on the framework map because genotyping data for the disease was not available for sufficient individuals.
Because the canine chromosomes are not cytologically characterized, and most early reports fail to agree on banding patterns and numbering assignments, we cannot identify cytologically the canine chromosome which contains the HCSMA linkage group. Most dog chromosomes are acrocentric or telocentric, and most are small, similar in length to the ''D'' group human chromosomes. Further advancements in chromosome identification and canine-human comparative mapping need to occur before we can identify the human homologue of the canine chromosome. Once this has occurred, candidate gene approaches may be used to actually identify, clone, and sequence the gene.
To date, the genetic basis of only a few types of human motor neuron disease have been elucidated, despite the high incidence of these diseases. Mutations in these genes account for only a small fraction of all human motor neuron diseases, and other, as yet unidentified genes are presumed responsible for the remainder. Our study shows that HCSMA is not associated with the SMN gene and is not, therefore, a molecular homologue of human spinal muscular atrophy, despite profound similarities between the two diseases. There are two reasons why this might occur. First, it could be that HCSMA and spinal muscular atrophy are entirely unrelated diseases caused by inherited mutations in genes from nonoverlapping pathways. Given their clinical similarity, this is unlikely. Second, it could be that defects in different genes of the same molecular pathway give both diseases similar presentations, and HCSMA identifies a different piece of the biochemical machinery. That HCSMA is not caused by mutations in a gene known to cause motor neuron disease in man increases its potential as a model for alternative forms of the human disease for which appropriate human pedigrees have not been identified. For this reason we expect HCSMA will ultimately be very important for understanding human, as well as canine, motor neuron disease.
